Close
R&D Blueprint
The R&D Blueprint is a global strategy and preparedness plan that allows the rapid activation of research and development activities during epidemics. Its aim is to fast-track the availability of effective tests, vaccines and medicines that can be used to save lives and avert large scale crises. With WHO as convener, the broad global coalition of experts who have contributed to the Blueprint come from medical, scientific and regulatory backgrounds. WHO Member States welcomed the development of the Blueprint at the World Health Assembly in May 2016.
From this point, this will be an editorial page composed of rows
R&D Blueprint
About us
The R&D Blueprint is a global strategy and preparedness plan that allows the rapid activation of research and development activities during epidemics. Its aim is to fast-track the availability of effective tests, vaccines and medicines that can be used to save lives and avert large scale crises. With WHO as convener, the broad global coalition of experts who have contributed to the Blueprint come from medical, scientific and regulatory backgrounds. WHO Member States welcomed the development of the Blueprint at the World Health Assembly in May 2016.
How it began
The West Africa Ebola epidemic saw the mobilization of numerous actors around the world to find medical technologies to address the disease and save lives. Some of those efforts brought results, such as the highly effective VSV-EBOV vaccine, while others showed large gaps in the way the global scientific and R&D community organizes itself during an epidemic. The Blueprint coalition considers those to be lessons gained and has developed a plan that leverages the successes and addresses the gaps /so that next time the world can be prepared.
How does the Blueprint work?
The R&D Blueprint uses a list of identified priority diseases. For each disease an R&D roadmap is created, followed by target product profiles. This is then used to guide the response to outbreaks in both urgent action and in developing ways to improve the global response for future epidemics.
Our Team
Mr. Martin Howell Friede
Coordinator of the Initiative for Vaccine research (IVR)
R&D Blueprint
Dr. Ana Maria Henao Restrepo
Medical Officer
R&D Blueprint
Dr. Vaseeharan Sathiyamoorthy
Coordinator
R&D Blueprint
Mrs. Claudia Nannei
Health Economist
R&D Blueprint
Dr. Marie-Pierre Preziosi
Medical Officer
R&D Blueprint
Ms. Emer Cooke
Director
Regulation and Prequalification
Virginia Benassi
Technical Officer
R&D Blueprint
Pierre Gsell
Technical Officer
R&D Blueprint
Massinissa Si Mehand
Technical Officer
R&D Blueprint
Close
Our work (placeholder for preview)